CliffBio
small molecule

FYCOMPA

PERAMPANEL

Loss of exclusivityJuly 2026latest FDA-listed patent expiry
CompanyCatalyst →View the full company profile on CliffBio

Drug detail

Brand nameFYCOMPA
Active ingredientPERAMPANEL
Strength6MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2012
Marketing statusRX

Listed patents

PatentExpiresType
8772497July 2026substance

More from Catalyst

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FYCOMPA patent cliff — loss of exclusivity July 2026 | CliffBio